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Summary
Background Friedreich’s ataxia is a progressive degenerative disorder caused by deﬁ ciency of the frataxin protein. 
Expanded GAA repeats within intron 1 of the frataxin (FXN) gene lead to its heterochromatinisation and transcriptional 
silencing. Preclinical studies have shown that the histone deacetylase inhibitor nicotinamide (vitamin B3) can 
remodel the pathological heterochromatin and upregulate expression of FXN. We aimed to assess the epigenetic and 
neurological eﬀ ects and safety of high-dose nicotinamide in patients with Friedreich’s ataxia.
Methods In this exploratory, open-label, dose-escalation study in the UK, male and female patients (aged 18 years or 
older) with Friedreich’s ataxia were given single doses (phase 1) and repeated daily doses of 2–8 g oral nicotinamide 
for 5 days (phase 2) and 8 weeks (phase 3). Doses were gradually escalated during phases 1 and 2, with individual 
maximum tolerated doses used in phase 3. The primary outcome was the upregulation of frataxin expression. We also 
assessed the safety and tolerability of nicotinamide, used chromatin immunoprecipitation to investigate changes in 
chromatin structure at the FXN gene locus, and assessed the eﬀ ect of nicotinamide treatment on clinical scales for 
ataxia. This study is registered with ClinicalTrials.gov, number NCT01589809.
Findings Nicotinamide was generally well tolerated; the main adverse event was nausea, which in most cases was mild, 
dose-related, and resolved spontaneously or after dose reduction, use of antinausea drugs, or both. Phase 1 showed a 
dose-response relation for proportional change in frataxin protein concentration from baseline to 8 h post-dose, which 
increased with increasing dose (p=0·0004). Bayesian analysis predicted that 3·8 g would result in a 1·5-times increase 
and 7·5 g in a doubling of frataxin protein concentration. Phases 2 and 3 showed that daily dosing at 3·5–6 g resulted 
in a sustained and signiﬁ cant (p<0·0001) upregulation of frataxin expression, which was accompanied by a reduction 
in heterochromatin modiﬁ cations at the FXN locus. Clinical measures showed no signiﬁ cant changes.
Interpretation Nicotinamide was associated with a sustained improvement in frataxin concentrations towards those 
seen in asymptomatic carriers during 8 weeks of daily dosing. Further investigation of the long-term clinical beneﬁ ts 
of nicotinamide and its ability to ameliorate frataxin deﬁ ciency in Friedreich’s ataxia is warranted.
Funding Ataxia UK, Ataxia Ireland, Association Suisse de l’Ataxie de Friedreich, Associazione Italiana per le Sindromi 
Atassiche, UK National Institute for Health Research, European Friedreich’s Ataxia Consortium for Translational 
Studies, and Imperial Biomedical Research Centre.
Copyright © Libri et al. Open Access article distributed under the terms of CC BY.
Introduction
Friedreich’s ataxia is the most common inherited ataxia 
in the white population, aﬀ ecting between 1 in 30 000 
and 1 in 50 000 people.1,2 It usually presents in childhood 
with a relentlessly progressive, predominantly sensory 
ataxia and dysarthria, and is associated with deafness, 
visual impairment, diabetes, and hypertrophic 
cardiomyopathy (a frequent cause of premature 
mortality).3 No eﬀ ective disease-modifying treatment 
exists, leaving many patients severely disabled by 
adulthood.
In 97% of cases, Friedreich’s ataxia is caused by the 
pathological expansion of a GAA triplet repeat within the 
ﬁ rst intron of both alleles of the frataxin (FXN) gene, 
which results in partial silencing of the gene, leading to 
frataxin protein deﬁ ciency.4,5 Most clinical trials so far 
have focused on ameliorating the downstream eﬀ ects of 
frataxin deﬁ ciency, with little success in modifying the 
natural history of the disease.6 Mariotti and colleagues7 
assessed the use of erythropoietin to upregulate frataxin, 
but did not report a signiﬁ cant eﬀ ect. In this study, we 
focus on a novel treatment aimed at correcting the 
primary defect, FXN gene silencing.
We previously showed8 that expanded GAA repeats can 
induce gene silencing in vivo. This mechanism resembles 
the archetypal epigenetic silencing known as position 
eﬀ ect variegation, in which abnormal proximity of a gene 
to highly condensed DNA (heterochromatin) results in 
the stochastic silencing of the gene in a proportion of 
cells that would normally express it. Indeed, FXN acquires 
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several hallmarks of hetero chromatin when silenced by a 
patho logical GAA-repeat expansion.9–11
A key feature of heterochromatin is the presence of 
methylation (me) at aminoacid position 9 of the histone 
H3 tail (H3K9me3) that protrudes from the basic subunit 
of chromatin, the nucleosome.12,13 This methylation was 
shown to be deposited by a powerful genetic modiﬁ er of 
position eﬀ ect variegation, the histone methyltransferase 
SUV39H.14,15 Subsequently other histone methyl-
transferases with this activity have been discovered.16,17 
H3K9me3 can be regarded as part of the histone or 
epigenetic code, which is then read by another powerful 
genetic modiﬁ er of position eﬀ ect variegation, hetero-
chromatin protein 1 (HP1). HP1 not only recognises and 
binds to H3K9me3, but can also recruit SUV39H, 
providing a mechanism for the propagation of 
heterochromatin along the DNA.14,15 Chromatin 
immunoprecipitation in cells from model systems and 
primary cells from patients with Friedreich’s ataxia showed 
an increase in H3K9me3 at the FXN locus and a reduction 
in acetylation of histone H3, the marker for active 
transcription.9–11 These discoveries have led to the ﬁ nding 
that inhibition of histone deacetylases (HDACs) can 
antagonise heterochromatin-mediated FXN gene silencing 
in cells from patients with Friedreich’s ataxia and in mouse 
models,9,11,18,19 and the development of a putative model for 
how such inhibitors might function (appendix p 2).20
Nicotinamide (vitamin B3) is a classical class III HDAC 
inhibitor.21–24 It has good bioavailability and rapidly 
penetrates all tissues, readily passing across the blood–
brain barrier.25–28 Nicotinamide has a good safety proﬁ le, 
having been given safely for 5 years at about 3 g (1·2 g/m²) 
per day to more than 250 individuals in an attempt to 
prevent diabetes in an at-risk population.29 However, the 
safety of nicotinamide in Friedreich’s ataxia has not 
previously been investigated. Our preclinical studies 
showed that nicotinamide can remodel the hetero-
chromatinised FXN locus and signiﬁ cantly upregulate 
FXN expression in primary cells from human beings, cell 
lines, and a mouse model for Friedreich’s ataxia.9 We 
aimed to assess whether high-dose nicotinamide could be 
used to safely upregulate FXN expression in patients with 
Friedreich’s ataxia, in an attempt to restore frataxin 
concentrations towards those in healthy individuals.
Methods
Study design and patients
In this exploratory, open-label, dose-escalation study, 
participants were recruited via the National Hospital for 
Neurology and Neurosurgery (London, UK) and the 
Imperial College Healthcare NHS Trust (London, UK). 
Male and female patients aged 18 years or older were 
eligible to participate if they had a documented 
diagnosis of Friedreich’s ataxia based on clinical criteria 
and a genetically conﬁ rmed GAA-repeat expansion on 
both alleles of the FXN gene. Exclusion criteria included 
hypersensitivity to nicotinamide and serious concurrent 
medical disorders or illnesses besides Friedreich’s 
ataxia, including clinically signiﬁ cant dysphagia and 
heart disorders (eg, severe atrial ﬁ brillation or 
hypertrophic cardiomyopathy). The trial registration 
page includes a full list of inclusion and exclusion 
criteria. Participants were screened for eligibility within 
about 28 days before receiving their ﬁ rst dose of 
nicotinamide, which was provided by Teofarma (Pavia, 
Italy) and produced in accordance with good manu-
facturing practice requirements.
The study was approved by the UK Medicines and 
Healthcare Products Regulatory Agency (MHRA; EudraCT 
2011-002744-27), the Riverside Research Ethics Committee 
(11/LO/0998), and the Imperial College London Joint 
Research & Compliance Oﬃ  ce. All participants provided 
written informed consent before any study-related pro-
cedures were initiated.
Procedures
The study was open label and divided into three phases. 
Phase 1 was a supervised, single-dose, dose-escalation 
phase, taking place over ﬁ ve visits, with a minimum 1-week 
washout period between each visit. Escalating doses 
(0, 2, 4, 6, 7, and 8 g) of oral nicotinamide were given on the 
basis of a prespeciﬁ ed scheme (appendix p 8) and patients 
were observed for 24 h after dosing. Dose escalation was 
adjusted or stopped on the basis of tolerability and 
antinausea treatments were given as needed. In phase 2, 
participants were given escalating doses for 5 consecutive 
days, and in phase 3 they received their maximum tolerated 
dose (if known from phase 2) daily for 8 weeks.
Phase 1 was used to determine the minimum dose at 
which nicotinamide could safely upregulate the FXN 
gene and to assess its pharmacokinetics and 
pharmacodynamics over 24 h. Blood samples for the 
measurement of plasma nicotinamide and FXN mRNA 
and frataxin protein concentrations (from separated 
peripheral blood mononuclear cells) were collected before 
treatment and at 2, 4, 8, and 24 h after dosing. Additionally, 
at the last dosing visit, blood samples were collected 
before dosing and 8 h after dosing for the measurement 
of heterochromatin modiﬁ cations at the FXN locus by 
chromatin immunoprecipitation. The analyses were done 
at the MRC Clinical Sciences Centre (Hammersmith 
Hospital, London, UK), as previously described (appendix 
pp 12–13).9,30,31 Because of encouraging results from 
phase 1, the original study protocol was amended to 
extend the study and include phase 3, at which time the 
lowest individual maximum tolerated dose identiﬁ ed in 
phase 1 (3·5g) was speciﬁ ed as the starting dose in phase 
2. At this stage the post-hoc clinical scale outcomes were 
also added to the study. The gap between phases 1 and 2 
varied between 3 and 7 months because of the time 
necessary to plan phase 3 and obtain relevant approvals 
from the ethics committee and the MHRA.
Phase 2 was used to assess the pharmacokinetics and 
pharmacodynamics of nicotinamide in relation to the 
See Online for appendix
For the trial registration page 
see http://www.clinicaltrials.gov/
ct2/show/NCT01589809
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upregulation of FXN expression, to determine whether 
this upregulation was associated with changes in 
chromatin, and to assess the safety and tolerability of 
nicotinamide after repeated administration over 
5 consecutive days. Patients were allocated to either 
nicotinamide treatment (n=8) or no treatment (n=2) at the 
discretion of the investigator, as speciﬁ ed in the protocol. 
The no-treatment control group was intended to allow the 
identiﬁ cation of any changes in FXN expression in the 
absence of nicotinamide over the treatment period. On 
the ﬁ rst day of phase 2, patients scheduled for active 
treatment were given the lowest individual maximum 
tolerated dose recorded in phase 1 (ie, 3·5 g). On 
subsequent days the dose was escalated to their individual 
maximum tolerated dose, but not higher than 4 g on day 2, 
5 g on day 3, or 6 g on days 4 and 5. As in phase 1, the 
dose-escalation schedule was adjusted or stopped on the 
basis of tolerability and antinausea treatments were given 
in the event of excessive nausea or vomiting. Blood 
samples for the measurement of nicotinamide plasma 
concentration, FXN mRNA expression, and frataxin 
protein concentration were collected each day before 
dosing and 2, 4, and 8 h after dosing.
Exploratory (post-hoc) neurological and speech 
dysarthria assessments were done and blood samples for 
chromatin analysis were taken on day 1 (predose) and 
day 5 (8 h post-dose). The neurological assessments used 
were the scale for the assessment and rating of ataxia 
(SARA)32 and the spinocerebellar ataxia functional index 
(SCAFI).33 Speech dysarthria was assessed with the 
Speech Intelligibility Test (Communication Disorders 
Software, Lincoln, NE, USA), a computer-based speech 
dysarthria assessment. SARA and SCAFI have been 
validated as sensitive indicators of neurological 
deterioration in Friedreich’s ataxia. The SCAFI score is 
derived from the scores obtained from three tasks: the 
8 m walk score (based on the time taken to walk 8 m); the 
nine-hole peg test score (based on the time taken to insert 
and remove pegs from a board); and the PATA score 
(based on the number of times the patient can say “pata” 
in 10 s). The Speech Intelligibility Test determines how 
easy it is to understand speech by recording the patient 
reciting set phrases and relies on the judgment of the 
investigator. Additionally, patients and their carers were 
asked to record their impressions about patients’ activities 
of daily living using part 2 of the FARS scale at the same 
study timepoints as the neurological assessments.34,35 
Increases in SARA or activities of daily living scores 
indicate clinical deterioration, as do decreases in SCAFI 
or Speech Intelligibility Test scores.
On completion of phase 2, patients entered immediately 
into phase 3 of the study, continuing daily treatment with 
nicotinamide at their maximum tolerated dose for a 
period of 8 weeks. Patients who were scheduled to receive 
no drug in phase 2 were gradually escalated to 3 g of 
nicotinamide within 1 week and then to their maximum 
tolerated dose (but not higher than 6  g). Patients were 
instructed to take their daily nicotinamide dose at home 
except when they returned to the investigational unit once 
a week for safety assessment and predose blood sampling 
to measure nicotinamide plasma concentration, FXN 
mRNA expression, and frataxin protein concentration. 
Neurological (SARA and SCAFI scales), speech dysarthria, 
and activities of daily living assessments were done twice 
Figure 1: Trial proﬁ le
18 patients assessed for eligibility
10 analysed
2 entered directly into study phase 2
6 excluded
 3 had severe illness
 1 had severe dysphagia
 1 had recent history of drug misuse
 1 was unable to provide informed consent
2 withdrawals
 1 discontinued because of a serious adverse 
  event unrelated to study treatment
 1 was unwilling to participate in study phase 2
10 entered study phase 1 (single dose, dose escalation)
 9 completed all ﬁve visits
 1 completed four out of ﬁve visits
10 entered study phase 2 (daily dosing for 5 days, 
  dose escalation)
 8 received escalating doses
 2 entered directly into phase 2 and received 
  no treatment 
10 entered phase 3 (daily dosing for 8 weeks, 
  maximum tolerated dose)
 10 received study drug
10 analysed
10 analysed
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per month. Additionally, patients were provided with 
weekly diaries to be completed daily for the entire duration 
of phase 3, until the end-of-study visit. Patients were asked 
to record the time of nicotinamide dose and number of 
tablets taken, missing doses, adverse events, and any 
concomitant drugs used. The end-of-dosing follow-up 
visit was scheduled to take place 1–3 weeks after the ﬁ nal 
dose of nicotinamide was given.
Statistical analysis
We calculated mean values for FXN mRNA expression 
and frataxin protein concentration, expressed as 
proportional change (simple ratio) relative to baseline at 
screening, by study day during phases 2 and 3 (up to and 
including week 8). We used a non-parametric regression 
to ﬁ t a trend line to the mean values, with 95% CIs 
derived by bootstrapping. Additionally, we used the non-
parametric version of the Hotelling test36 (with a χ² 
approximation) to test the null hypothesis of no increase 
in frataxin protein concentration relative to baseline.
We analysed the proportional change in frataxin 
protein concentration from baseline data in phase 1 
using a repeated-measures linear regression model to 
examine the relation between relative change and dose, 
taking into account the association between repeated 
measurements for individual patients. For the purpose of 
selecting the doses to be used in phase 2, we also analysed 
these data using a Bayesian dose-response model37 to 
generate predicted values of doses likely to yield relative 
increases in frataxin concentration of 1·5 and 2·0 times.
To assess changes in chromatin, we analysed enrichment 
for H3K9me3 and H3 panacetylation using a two-tailed 
paired Student’s t test in Microsoft Excel for Mac 2011 
(version 14.3.5). In phase 3, comparison of clinical scores 
between baseline and week 8 was also done using a two-
tailed paired Student’s t test in the same software.
For all cases in which data were missing, no imputation 
was done and the missing datapoints were omitted from 
the analysis. The only exception to this approach was for 
the non-parametric Hotelling test, wherein missing data 
for changes in frataxin protein concentration were 
imputed by setting the missing value equal to the null 
hypothesis value of 1·0. 
Analyses of pharmacokinetics and pharmacodynamics 
for phases 2 and 3 were done on an intention-to-treat 
basis. Data from all patients in the treatment group were 
analysed irrespective of the dose they received.
Statistical analyses other than Student’s t tests were 
done with SAS version 9.3, R version 3.0.1, or OPENBUGS 
version 3.2.2.
The study is registered at ClinicalTrials.gov, number 
NCT01589809.
Role of the funding source
The funders of the study had no role in data collection, 
data analysis, data interpretation, or writing of the report, 
although Ataxia UK had some input into the study 
design, particularly in the early stages. All authors had 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Of 18 patients screened between June 8, 2012, and 
June 24, 2013, ten met the eligibility criteria and were 
enrolled into phase 1 of the study, with follow-up for 
phase 1 taking place between June, 2012, and October, 
2012 (ﬁ gure 1). Nine participants completed phase 1 
and one completed four out of ﬁ ve visits, but withdrew 
before the ﬁ nal visit because she found the hospital 
environment stressful. All remaining patients were 
oﬀ ered the opportunity to continue to the multiple-dose 
phases of the study (phases 2 and 3), but one was 
excluded as a safety precaution because of an episode of 
Dose Total number 
of episodes
0 g 2 g 3·5 g 4 g 6 g 7–8 g
Nausea 14 (24%)*
Mild 0 0 0 1 4 2 7
Moderate 0 0 1 1 5 0 7
Headache 11 (19%)*
Mild 0 0 0 2 1 1 4
Moderate 0 0 0 1 3 1 5
Severe 0 0 0 0 2 0 2
Vomiting 8 (14%)*
Mild 0 0 0 2 3 1 6
Moderate 0 0 0 0 1 0 1
Severe 0 0 0 0 1 0 1
Fatigue 4 (7%)*
Mild 0 0 0 1 1 1 3
Moderate 0 0 0 1 0 0 1
Fever 1 0 0 2 0 0 3 (5%)*
Presyncope 0 0 0 1 1 1 3 (5%)*
Hypotension 0 1 0 0 1 0 2 (3%)*
Adverse events that occurred only once are not shown. *Data are total number of episodes (percentage of total adverse 
events reported).
Table 2: Most common adverse events during study phase 1, by dose
Phase 1 (n=10) Phases 2 and 3 (n=10)
Women 6 7
Age 33 (23–54) 33 (19–54)
Ethnic origin
White (British or Irish) 9 9
Asian (Bangladeshi) 1 1
SARA at baseline 16·3 (5·0–31·5) 16·3 (5·0–31·0)
Age at onset (years) 17·9 (8·1) 21·7 (9·5)
Onset after age 25 years 2 4
Years of disease 15·4 (6·7) 14·0 (8·0)
Data n, mean (SD), or median (range). SARA=scale for the assessment and rating of ataxia.
Table 1: Baseline demographic and clinical characteristics
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atrial tachycardia associated with a respiratory infection 
that occurred 2 months after completion of phase 1 and 
before the start of phase 2; this event was similar to a 
previous episode that predated the study. Two additional 
patients (also recruited during the screening period, 
which continued until suﬃ  cient patients for each phase 
were enrolled) were enrolled directly into phase 2, and 
were allocated to receive no treatment during this 
phase. These two patients were used as a control group 
to allow us to determine the eﬀ ect of the hospital 
environment on frataxin concentrations and the other 
measurements. All 10 patients completed phase 2 and 
continued into phase 3, which took place between 
January, 2013, and August, 2013, and during which all 
patients received treatment. Data from all completed 
patients were analysed. Table 1 summarises the 
demographic and baseline clinical characteristics of the 
participants (including baseline disease severity as 
measured by SARA).
Nicotinamide was generally well tolerated. The main 
adverse event was nausea, which in most cases was mild, 
dose-related, and resolved either spontaneously or after 
dose reduction, use of antinausea drugs, or both. The 
dose escalation showed an increase in adverse events as 
the dose increased, thereby allowing identiﬁ cation of a 
maximum tolerated dose for each patient. Increases in 
abnormal results from liver function tests in three out of 
ten patients occurred only when taking high doses—in 
two cases these eﬀ ects were mild to moderate and self-
limiting and in one case they were severe, but all resolved 
with reduction of the nicotinamide dose (tables 2–4, 
appendix pp 9–10). No clinically signiﬁ cant changes in 
vital signs or physical ﬁ ndings were seen, and no serious 
adverse events occurred while patients were taking 
nicotinamide. The only adverse events in the no-treatment 
group (phase 2) were related to the common cold (nasal 
congestion, cough, and sore throat), which occurred in 
one patient.
In phase 1, we noted a dose-response relation for the 
mean proportional change in frataxin protein 
concentration at 8 h over the range of 2–8 g nicotinamide 
given as a single oral dose (p=0·0004; appendix p 3). 
Frataxin concentrations returned to baseline by 24 h. 
Predicted doses from the Bayesian model were 3·8 g for 
a 1·5-times increase in frataxin concentration, and 7·5 g 
for a 2·0-times increase.
The pharmacokinetic analysis population included all 
participants who had received at least one dose of 
nicotinamide (n=12). In phase 1, nicotinamide reached a 
dose-dependent mean peak plasma concentration at 
1–3 h (appendix p 4). Plasma concentrations subsequently 
declined with an apparent half-life (estimated from a 
Bayesian one-compartment model) of 12·1 h, which is 
similar to the pharmacokinetics of nicotinamide 
reported by other investigators.28,38,39 In phase 2, repeated 
administration of nicotinamide of 3·5–6 g resulted in a 
dose-dependent increase in nicotinamide plasma peak 
and trough concentrations (ﬁ gure 2), with steady-state 
plasma concentrations from week 2 onwards in phase 3 
(ﬁ gure 3).
Further analysis of the data from phase 1 provided 
insight into the mechanism by which nicotinamide might 
upregulate FXN expression. Plasma nicotinamide 
concentration reached its peak value ﬁ rst (2 h), followed by 
FXN mRNA expression (4 h), and then by frataxin protein 
concentration (8 h; appendix pp 4–5). This ﬁ nding is 
consistent with the hypothesis that nicotinamide acts on 
gene transcription. After decay of nicotinamide, FXN 
mRNA expression fell more rapidly than frataxin protein 
Number of 
events
Number of 
participants 
aﬀ ected (n=10)
Nausea 58 10
Headache 15 5
Lightheadedness 13 6
Vomit 7 5
Hypersomnia 7 1
Fatigue 6 3
Diarrhoea 6 4
Raised alanine transaminase 5 3
Fall 4 3
Anorexia 3 3
Raised aspartate aminotransferase 3 2
Migraine 3 1
Dizziness 2 1
Sore throat 2 1
Retching 2 1
Cold 2 2
Fever 2 2
Infections 2 2
Cough 2 2
Anaemia 2 2
Flu-like symptoms 2 1
Adverse events that occurred only once are not shown.
Table 3: Most common adverse events during study phases 2 and 3
3 g 3·5 g 4 g 5 g 6 g Total
Mild nausea 4 2 44 0 0 50
Moderate nausea 1 0 4 2 0 7
Severe nausea 0 0 0 0 1 1
Mild vomiting 0 1 1 1 0 3
Moderate vomiting 0 0 0 1 0 1
Severe vomiting 0 0 2 0 1 3
Mild LFT abnormality 0 0 2 0 3 5
Moderate LFT abnormality 0 0 1 0 1 2
Severe LFT abnormality 0 0 0 0 1 1
LFT=liver function tests.
Table 4: Nausea, vomiting, and abnormal LFT results during study 
phases 2 and 3, by dose
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concentration, in line with the fact that the half-life of the 
protein is higher than that of the mRNA.40 A similar 
pattern was seen after multiple dosing in phase 2 (ﬁ gure 2).
To further investigate the mechanism of FXN 
upregulation, we used chromatin immunoprecipitation 
on peripheral blood mononuclear cells before and after 
nicotinamide treatment, which showed a signiﬁ cant 
reduction in the characteristic heterochromatin modiﬁ -
cation H3K9me3 in the regions ﬂ anking the FXN GAA-
repeat expansion (upstream p=0·0054; downstream 
p=0·0186), accompanied by a non-signiﬁ cant increase in 
acetylation (upstream p=0·8472; downstream p=0·9988) 
of histone H3 (ﬁ gure 2). Taken together, these results are 
consistent with the original hypothesis that nicotinamide 
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Figure 2: Pharmacokinetics and pharmacodynamics of daily doses of nicotinamide over 5 days (study phase 2)
Data are mean values for nicotinamide plasma concentrations and proportional changes in FXN mRNA expression and frataxin protein concentration in 
peripheral blood mononuclear cells (simple ratio relative to baseline) for no nicotinamide (A; n=2, error bars show range) and doses of 3·5–6 g per day (B; n=8, 
error bars show SEs) over 5 days. Green arrows indicate the time of dosing. Data for individual patients are shown in the appendix (pp 6–7). (C, D) The chromatin 
immunoprecipitation assay used antibodies against heterochromatic (inactive) H3K9me3 and the euchromatic (active) H3 acetylation histone marks, and the 
DNA obtained was analysed by real-time PCR with primers for intron P3 (IntP3) and intron P4 (IntP4) ﬂ anking the (GAA)n repeats in intron 1 of the FXN gene. 
(D) Data are mean values of relative enrichment (simple ratio relative to baseline). Error bars show SEs (n=8). UTR=untranslated region. 
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Figure 3: The eﬀ ect of nicotinamide on FXN mRNA expression and frataxin protein concentration over 8 weeks (study phase 3) and a non-parametric 
regression model of this eﬀ ect (study phases 2 and 3 combined)
(A) Pharmacokinetics and pharmacodynamics of daily dosing with nicotinamide over 8 weeks (study phase 3). Data are mean values for nicotinamide plasma 
concentrations and proportional changes in FXN mRNA expression and frataxin protein concentration in peripheral blood mononuclear cells (simple ratio relative 
to predose baseline) for doses of 3·5–6 g per day (n=10, error bars show SEs). (B) Spaghetti plot of data for the concentration of frataxin protein in peripheral blood 
mononuclear cells by individual patients over 8 weeks (study phase 3; absolute mRNA data for individual patients are shown in the appendix [p 7]). Each coloured 
line indicates the data from one patient; the thick black line indicates the mean for each datapoint (error bars show SEs). The grey zone indicates the range of 
frataxin protein expression seen in asymptomatic Friedreich’s ataxia carriers and the dashed line indicates the average for this population.30 (C) Non-parametric 
regression model for the proportional changes in frataxin protein concentration in peripheral blood mononuclear cells (simple ratio relative to baseline at 
screening) with daily nicotinamide treatment over 60 days (study phases 2 and 3). The dotted line indicates the mean of the raw data. The solid black line indicates 
the ﬁ tted non-parametric trend line, and the blue lines indicate the 95% CI of the regression trend line, generated by bootstrapping. The graph shows a sustained 
and signiﬁ cant (p<0·0001) increase in frataxin protein, with the lower bound of the CI above the null value of 1·0 at all timepoints.
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can antagonise the pathological heterochromatinisation 
at the FXN gene in patients with Friedreich’s ataxia, 
thereby facilitating restoration of FXN expression.
Taking into account tolerability results from phase 1, 
patients were prescribed between 3·5 g and 6 g nico-
tinamide daily in phases 2 and 3. We noted a sustained 
and signiﬁ cant (p<0·0001) increase in frataxin protein 
concentration during both phases (ﬁ gure 3C), with the 
lower bound of the 95% CI remaining above the null 
value of 1·0 at all timepoints. However, the response was 
variable, with two of the ten patients showing little 
change in frataxin concentration (ﬁ gure 3B).
No signiﬁ cant eﬀ ects were seen on the clinical scale 
ratings for disease progression over study phases 2 and 3, 
although a slight, non-signiﬁ cant improvement was seen 
in the more subjective assessment of activities of daily 
living (table 5).
Discussion
Our results showed a signiﬁ cant and sustained upregu-
lation of frataxin protein in most patients over an 8-week 
period of daily dosing with nicotinamide. Thus, the 
present study is one of the ﬁ rst clinical studies to 
establish the proof-of-concept of a treatment aimed at 
halting the progression of Friedreich’s ataxia by restoring 
the expression of FXN using an HDAC inhibitor (panel).
Our chromatin immunoprecipitation results showed 
that nicotinamide treatment led to a signiﬁ cant reduction 
in the heterochromatin modiﬁ cation H3K9me3 and a non-
signiﬁ cant increase in H3 acetylation in the regions 
ﬂ anking the FXN GAA-repeat expansion. Obviously it was 
not possible to analyse these eﬀ ects directly in the tissues 
aﬀ ected in Friedreich’s ataxia. However, these data are 
consistent with results obtained from the cerebellum of 
mice carrying a human FXN gene with a GAA-repeat 
expansion9 and support the hypothesis that nicotinamide is 
acting at the chromatin level to antagonise heterochromatin. 
Interestingly, nicotinamide was previously shown not only 
to inhibit deacetylation of histones, but also deacetylation 
of the histone methyl transferase SUV39H,24 thereby 
inhibiting its activity, and provide an additional putative 
mechanism by which nicotinamide inhibits hetero-
chromatin formation at the FXN gene.
Our study represents one of the ﬁ rst attempts to assess 
an epigenetic therapeutic approach for a disease other 
than cancer, introducing a potential novel use for a widely 
available drug in doses that were previously shown to be 
well tolerated by healthy individuals for a long period.26,29 
Diseases other than Friedreich’s ataxia caused by similar 
mechanisms could also be amenable to such a therapeutic 
approach—eg, other repeat-induced diseases and those 
caused by mutations in the regulatory elements of genes. 
Interestingly, nicotinamide has been investigated in the 
past for its neuroprotective role in the modulation of 
cellular energy metabolism together with coenzyme Q10 
in Parkinson’s disease,41 suggesting a possible additional 
therapeutic beneﬁ t in Friedreich’s ataxia.
Diﬀ erence from baseline 
(95% CI)
p value
SARA –0·4 (–2·2 to 1·5) 0·69
SCAFI 0·1 (–0·1 to 0·3) 0·31
8 m walk –0·1 (–0·2 to 0·1) 0·18
Nine-hole peg test 0·1 (0·0 to 0·3) 0·10
PATA 0·1 (–0·2 to 0·5) 0·39
SIT –0·1 (–0·1 to 0·0) 0·15
ADL –4·1 (–9·0 to 0·7) 0·07
Data are mean diﬀ erences in scores between the start of phase 2 and the end of 
phase 3 (week 8), with associated p values. SARA=scale for the assessment and 
rating of ataxia. SCAFI=spinocerebellar ataxia functional index. SIT=Speech 
Intelligibility Test. ADL=activities of daily living.
Table 5: Clinical scale ratings for disease progression (study phases 2 and 3)
Panel: Research in context
Systematic review
Our initial ﬁ nding8 that GAA-triplet repeat expansions, which 
cause Friedreich’s ataxia by silencing the frataxin (FXN) gene, 
could induce heterochromatin-mediated gene silencing in 
transgenic mice led us to the hypothesis that epigenetic 
modiﬁ ers could provide a novel therapeutic approach for 
Friedreich’s ataxia. Subsequently, several groups conﬁ rmed 
that the FXN gene in patients with Friedreich’s ataxia was 
heterochromatinised,9–11 providing support for our hypothesis. 
Preclinical studies9,11,18 have shown that HDAC inhibitors can 
partly restore frataxin expression towards asymptomatic 
levels. We searched PubMed for articles published in any 
language between March 8, 1996, and Dec 10, 2013, using 
combinations of the search terms: “histone deacetylase 
inhibitor”, “HDAC inhibitor”, “nicotinamide”, “vitamin B3”, 
“Friedreich’s ataxia”, “heterochromatin”, “epigenetics”, and 
“clinical trial”. We identiﬁ ed no reports of clinical studies 
investigating the use of histone deacetylase (HDAC) inhibitors 
in patients with Friedreich’s ataxia. The author of an extensive 
review of clinical trials for Friedreich’s ataxia6 similarly did not 
identify any such studies. Our previous ﬁ nding9 that the HDAC 
inhibitor nicotinamide (vitamin B3) could partly restore 
expression of the FXN gene in model systems led us to 
investigate whether a similar upregulation of FXN could be 
achieved in patients.
Interpretation
In this exploratory study, we have identiﬁ ed safe and 
well-tolerated doses of nicotinamide, which when given to 
patients with Friedreich’s ataxia led to partial reversal of the 
abnormal heterochromatinisation of the FXN gene and 
restoration of frataxin concentration towards asymptomatic 
levels. These ﬁ ndings provide a proof-of-concept that such an 
approach might provide a means of restoring frataxin 
concentrations in the long term, which could prevent 
deterioration in Friedreich’s ataxia. This study is not adequate to 
support the use of nicotinamide as a treatment for Friedreich’s 
ataxia, but our ﬁ ndings suggest that further studies of its 
long-term clinical eﬃ  cacy are warranted.
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The doses of nicotinamide used in this study are 
consistent with previous data about nicotinamide safety 
and tolerability,26 but are much higher than the 
recommended daily vitamin B3 requirement. However, 
the drug was well tolerated when given for an 8-week 
period with nausea as the main adverse reaction; this was 
readily controlled with the use of antiemetics and by 
modiﬁ cation of the dose. Dose-related increases in 
abnormal liver function test results should be taken into 
account when deciding on doses for longer studies.
Despite inherent variability between individuals and 
some changes in dose in response to adverse events, our 
results showed a signiﬁ cant upregulation in frataxin 
protein concentrations. However, two patients seemed 
to be relative non-responders. Interestingly, these 
patients had the lowest frataxin protein concentrations 
at baseline of the ten patients who took part in phase 3. 
One possible explanation is that the FXN gene is so 
strongly repressed in these patients that it is refractory to 
the eﬀ ect of nicotinamide. Among the eight patients 
who responded to nicotinamide, absolute concentrations 
of frataxin protein ranged between 17·66 and 
22·14 pg per μg of of total protein extract from peripheral 
blood mononuclear cells at week 8. These concentrations 
are within the range previously reported for Friedreich’s 
ataxia carriers (15·5–50·6 pg/μg; mean 26·5 pg/μg 
[SD 7·1]),30 whereas the range for healthy individuals is 
higher (25·3–55·9 pg/μg; mean 38·6 pg/μg [7·6]). Since 
carriers are asymptomatic, this ﬁ nding raises the 
possibility that sustained correction of frataxin deﬁ ciency 
in patients could be beneﬁ cial and modify disease 
progression. The eﬀ ect of restoration of frataxin in 
Friedreich’s ataxia is currently unknown. Several 
treatment strategies that are believed to address the 
causes of neurodegenerative diseases suggest diverse 
outcomes. For example, replacing MECP2 in RETT 
syndrome42 could result in reversal of the disease 
phenotype, whereas in Alzheimer’s disease removal of 
plaques is believed by some researchers not to be disease 
modifying.43
The clinical scale assessments were post-hoc and 
exploratory, to assess disease progression or improvement 
and the association between frataxin concentration and 
clinical outcomes. The rate of neurological decline in 
Friedreich’s ataxia is so slow6 that any preventive eﬀ ect of 
nicotinamide would be unlikely to be identiﬁ ed from the 
objective clinical rating scores over the short duration of 
this study. Although some short studies have shown 
improvements in clinical rating scales,6,44,45 albeit with 
diﬀ erent drugs, timescales, and clinical scales, this 
study did not show improvements. Such scales might 
not be sensitive enough to capture small changes. 
However, such changes might have been picked up by 
the more subjective activities of daily living survey, with 
the caveats that this is an open-label study (making such 
assessment subject to bias) and that the change in this 
score was not signiﬁ cant. Increasing frataxin expression 
towards asymptomatic concentra tions might be 
expected to prevent further deterioration, but such an 
eﬀ ect could only be captured by a longer and larger 
study.6
Our results have shown that nicotinamide is rapidly 
absorbed after oral administration and is generally well 
tolerated in patients with Friedreich’s ataxia after repeated 
daily dosing for 8 weeks. Moreover, consistent with 
preclinical ﬁ ndings, frataxin protein concentrations in 
peripheral blood mononuclear cells are increased towards 
those seen in asymptomatic carriers. This preliminary 
study is not adequate to support the use of nicotinamide 
as a treatment for Friedreich’s ataxia, but trials to establish 
safety and clinical eﬃ  cacy over a suﬃ  cient timescale to 
measure clinical decline are warranted.
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